All In Biotech

Drug Trial Radar · NCT03260491

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

312

Actual

Start

Oct 30, 2017

Primary completion

Dec 1, 2025

Study completion Jul 30, 2027

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Aug 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion. In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation after disease progression during/after EGFR tyrosine kinase inhibitor (TKI) therapy. In Dose Expansion, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCLC (ie, without EGFR-activating mutations) with disease progression during/after systemic treatment for locally advanced or metastatic disease. In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS-G12C mutation after progression on the most recent line of therapy (Cohort 5).

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)

Interventions

  • HER3-DXd (FL-DP)Drug

    HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).

  • HER3-DXd (CTM-1 Lyo-DP)Drug

    HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.

  • HER3-DXd (CTM-3 Lyo-DP)Drug

    HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities (DLTs) during dose escalationTime frame: 21 days of Cycle 1
  2. Summary of adverse events during dose escalationTime frame: By the global end of trial date, approximately within 36 months
  3. Overall response rate (ORR) assessed by Blinded Independent Central Review (BICR) Committee during dose expansion (Dose Expansion Cohorts 1, 2, 3a, 3b, and Cohort 5)Time frame: Approximately within 36 months
  4. Maximum serum concentration (Cmax) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4)Time frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.
  5. Area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf) and up to last quantifiable time (AUC[last]) of HER3-DXd, total anti-HER3 antibody, and MAAA-1181a during dose expansion (Cohort 4)Time frame: During the first 5 cycles (each cycle is 21 days), including an intensive sampling schedule: pre-dose, end of infusion (EOI), 2 hour (hr), 4 hr, 8 hr post infusion, Day 8, and Day 15.

Locations

37 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • University of California San Diego

    La Jolla, California

  • Pacific Shores Medical Group

    Long Beach, California

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • NYU Langone Health - NYU Medical Oncology Associates

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Gabrail Cancer Center (GCC) - Canton Facility

    Canton, Ohio

  • University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute/Tennesse Oncology

    Nashville, Tennessee

  • Oncology Consultants P.A.

    Houston, Texas

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Northwest Medical Specialties

    Tacoma, Washington

  • National Cancer Center Hospital East (NCCHE) - Kashiwa Campus

    Kashiwa-Shi, Japan

  • Kurume University - Kurume University Hospital - Respiratory Diseases Center

    Kurume-Shi, Japan

  • Kindai University Hospital

    Osaka, Japan

  • Shizuoka Cancer Center

    Shizuoka, Japan

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR)

    Tokyo, Japan

  • Netherlands Cancer Institute

    Amsterdam, Netherlands

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • NEXT Oncology - Hospital Quironsalud Barcelona

    Barcelona, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital General Universitario Gregorio Maranon (HGUGM)

    Madrid, Spain

  • Clinica Universidad Navarra(Madrid)

    Madrid, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal (CIOCC)

    Madrid, Spain

  • Hospital Universitario Quirónsalud Madrid

    Madrid, Spain

  • Clínica Universidad de Navarra (Pamplona)

    Pamplona, Spain

  • Chung Shan Medical University Hospital

    Taichung, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.